NASDAQ:CADL Candel Therapeutics Q3 2026 Earnings Results & Report $6.42 -1.97 (-23.42%) As of 12:53 PM Eastern This is a fair market value price provided by Massive. Learn more. Candel Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.28 versus the -$0.3372 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeAfter Market ClosesConference Call DateNovember 12, 2026Conference Call9:30 AM ET Candel Therapeutics EPS ResultsActual EPS-$0.28Consensus EPS -$0.3372Beat/MissBeat by +$0.0572One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCandel Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Candel Therapeutics Q3 2026 Earnings FAQ Did Candel Therapeutics beat earnings estimates for Q3 2026? Candel Therapeutics (NASDAQ:CADL) reported earnings of -$0.28 per share for Q3 2026, beating the consensus estimate of -$0.3372. The report was announced on Friday, November 13, 2026. Candel Therapeutics Earnings HeadlinesCADL INVESTIGATION: Candel Therapeutics Investigated for Securities Fraud by Block & Leviton: Investors Should Contact the Firm25 minutes ago | globenewswire.comCandel Therapeutics Outlines Mid-2027 BLA Plan For Aglatimagene Following Q3 Results2 hours ago | rttnews.comGOP wipeout … but here's WORSE news for the marketA 3 trillion dollar crisis may be building beneath the surface of the stock market, retirement accounts, pensions, and even banks. Reuters reports alarm bells echoing 2007 subprime warnings, and bestselling author Dr. Martin Weiss says this one may already be underway. His free briefing outlines five steps investors are considering to help protect their portfolios.November 13 at 1:00 AM | Weiss Ratings (Ad)Candel Therapeutics shares tumble 39% after-hours: Here's why2 hours ago | msn.comCandel Therapeutics stock plummets 35% on prostate cancer BLA delay2 hours ago | finance.yahoo.comCandel Shares Fall on Wider Loss From Operation, FDA DiscussionNovember 12 at 11:25 PM | marketscreener.comMSee More Candel Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Candel Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Candel Therapeutics and other key companies, straight to your email. Email Address About Candel TherapeuticsCandel Therapeutics (NASDAQ:CADL) is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications. Its research and development activities are focused on advancing these candidates through clinical trials.View Candel Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
